CLINDESSE Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5993856 | PADAGIS US | Pharmaceutical preparations and methods for their administration |
Nov, 2017
(6 years ago) | |
| US6899890 | PADAGIS US | Bioadhesive drug delivery system |
Apr, 2023
(11 months ago) | |
| US9789057 | PADAGIS US | Pharmaceutical delivery system |
Dec, 2026
(2 years from now) | |
Clindesse is owned by Padagis Us.
Clindesse contains Clindamycin Phosphate.
Clindesse has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Clindesse are:
- US5993856
- US6899890
Clindesse was authorised for market use on 30 November, 2004.
Clindesse is available in cream;vaginal dosage forms.
Clindesse can be used as method of treating bacterial vaginosis.
The generics of Clindesse are possible to be released after 02 December, 2026.
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 30 November, 2004
Treatment: Method of treating bacterial vaginosis
Dosage: CREAM;VAGINAL
How can I launch a generic of CLINDESSE before it's drug patent expiration?
More Information on Dosage
CLINDESSE family patents
